Literature DB >> 1528338

Clinical studies of destructive spondyloarthropathy in long-term hemodialysis patients.

H Maruyama1, F Gejyo, M Arakawa.   

Abstract

Destructive spondyloarthropathy (DSA) has recently been recognized in hemodialysis patients. This study was undertaken to assess the prevalence, preferred sites, risk factors, early radiological manifestations, magnetic resonance imaging (MRI) and relation to other radiological features and biochemical variables in DSA. In 405 patients undergoing dialysis for 0.2-20.5 years (average 8.2) with a mean age of 51.9 years (range 24-84), a diagnosis of DSA was made for 37 (9.1%). The preferred site of DSA was the lower cervical spine. MRI indicated a low signal intensity of the involved vertebral regions on both T1- and T2-weighted images and thus appeared useful in the exclusion of osteomyelitis showing high-intensity T2-weighted images. The patients were divided into three groups according to radiological findings: those showing (A) the presence of DSA, (B) vertebral rim erosion (VRE) without DSA, and (C) the absence of DSA and VRE. Patient age at onset of dialysis (p less than 0.01) and duration of hemodialysis (p less than 0.05) appeared to be the associated risk factors for DSA. DSA was found correlated with carpal tunnel syndrome (p less than 0.01), carpal bone cystic radiolucency (p less than 0.01), and amyloid deposit (p less than 0.01). All the groups were essentially the same with respect to the incidence of ectopic calcification, secondary hyperparathyroidism, biochemical markers and sex distribution. The results of this study show DSA to be associated with dialysis amyloidosis.

Entities:  

Mesh:

Year:  1992        PMID: 1528338     DOI: 10.1159/000186832

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  8 in total

1.  Amyloid, advanced glycation end products, and dialysis related arthropathy.

Authors:  S P McDonald; P T Coates; A P Disney
Journal:  Ann Rheum Dis       Date:  1998-04       Impact factor: 19.103

Review 2.  Beta-2 Microglobulin Amyloidosis: Past, Present, and Future.

Authors:  Ignacio Portales-Castillo; Jerry Yee; Hiroshi Tanaka; Andrew Z Fenves
Journal:  Kidney360       Date:  2020-10-21

3.  The relationship between the type of destructive spondyloarthropathy and its 10 years ago cervical spine alignment.

Authors:  Koji Maruyama; Yukihiro Matsuyama; Makoto Yanase; Yoshihito Sakai; Yoshito Katayama; Shiro Imagama; Zenya Ito; Norimitsu Wakao; Yasutsugu Yukawa; Keigo Ito; Mitsuhiro Kamiya; Tokumi Kanemura; Koji Sato; Naoki Ishiguro
Journal:  Eur Spine J       Date:  2009-04-08       Impact factor: 3.134

Review 4.  Update on imaging in chronic kidney disease-mineral and bone disorder: promising role of functional imaging.

Authors:  Sharjeel Usmani; Najeeb Ahmed; Gopinath Gnanasegaran; Fahad Marafi; Tim van den Wyngaert
Journal:  Skeletal Radiol       Date:  2021-09-15       Impact factor: 2.199

5.  Differential diagnosis of tumoral lesions in the spinal canal in patients undergoing hemodialysis.

Authors:  Keiji Wada; Yasuaki Murata; Yoshiharu Kato
Journal:  Asian Spine J       Date:  2015-04-15

Review 6.  Dialysis-related amyloidosis: challenges and solutions.

Authors:  R Scarpioni; M Ricardi; V Albertazzi; S De Amicis; F Rastelli; L Zerbini
Journal:  Int J Nephrol Renovasc Dis       Date:  2016-12-07

7.  Quadriplegia caused by an epidural abscess occurring at the same level of cervical destructive spondyloarthropathy: a case report.

Authors:  Jun-Seok Lee; Ji-Hyun Ryu; Jong-Tae Park; Ki-Won Kim
Journal:  BMC Musculoskelet Disord       Date:  2017-01-10       Impact factor: 2.362

8.  Structural Features of Amyloid Fibrils Formed from the Full-Length and Truncated Forms of Beta-2-Microglobulin Probed by Fluorescent Dye Thioflavin T.

Authors:  Anna I Sulatskaya; Natalia P Rodina; Dmitry S Polyakov; Maksim I Sulatsky; Tatyana O Artamonova; Mikhail A Khodorkovskii; Mikhail M Shavlovsky; Irina M Kuznetsova; Konstantin K Turoverov
Journal:  Int J Mol Sci       Date:  2018-09-14       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.